Evidence map›Paper›PMID 36371162›Full record

ArticleBMC neurology2022

MSmonitor-plus program and video calling care (MPVC) for multidisciplinary care and self-management in multiple sclerosis: study protocol of a single-center randomized, parallel-group, open label, non-inferiority trial.

M Hoving, P J Jongen, S M A A Evers, M A Edens, E M P E Zeinstra

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in BMC neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05242731 (MonSter Study, Telemonitoring and Connected Care Applied to Multiple Sclerose), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 79% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05242731 naunknown statusnot on this map

MonSter Study, Telemonitoring and Connected Care Applied to Multiple Sclerose

TypeinterventionalSponsorIsalaRan2021 to 2025Enrolled208ConditionsMultiple SclerosisArmsMSmonitor, a self-management/education program with e-health interventions, Video calling program "Better-close", Researchmanager program
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

M HovingMultiple Sclerosis Center, Department of Neurology, Isala Hospital, Zwolle, the Netherlands. m.hoving@isala.nl.ORCID http://orcid.org/0000-0003-2781-8139
P J JongenMS4 Research Institute, Nijmegen, the Netherlands.
S M A A EversDepartment of Health Services Research (HRS), Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, the Netherlands.
M A EdensEpidemiology Unit, Department of Innovation and Science, Isala Hospital, Zwolle, the Netherlands.
E M P E ZeinstraMultiple Sclerosis Center, Department of Neurology, Isala Hospital, Zwolle, the Netherlands.
Isala · NLDepartment of Health · TWMaastricht University · NLUniversity Medical Center Groningen · NL

Funding

Innovatie en wetenschapsfonds Isala 20.015National Multiple Sclerosis Foundation (NL) OZ2020-001
6 · The paper itself

Abstract

backgroundWe designed a new multi-modal version of the MSmonitor, called the MSmonitor-Plus and Video calling Care (MPVC), a self-management and education program with e-health interventions that combines frequent use of specific questionnaires with video calling in treating multiple sclerosis (MS) patients.

objectiveTo assess the effectiveness, cost-effectiveness and feasibility of MPVC compared to care as usual (CAU), with the goal of achieving equal or better quality of life for MS patients and their partners/informal caregivers. Our hypothesis is that by using MPVC, monitoring will become more efficient, that patients' self-efficacy, quality of life, and adherence to treatment will improve, and that they will be able to live their lives more autonomously.

methodsA randomized, parallel-group, open label, non-inferiority trial will be conducted to compare MPVC with CAU in MS patients and their partners/informal caregivers. A total of 208 patients will be included with follow-up measurements for 2 years (at baseline and every 3 months). One hundred four patients will be randomized to MPVC and 104 patients to CAU. Partners/informal caregivers of both groups will be asked to participate. The study will consist of three parts: 1) a clinical effectiveness study, 2) an economic evaluation, and 3) a process evaluation. The primary outcome relates to equal or improved disease-specific physical and mental quality of life of the MS patients. Secondary outcomes relate to self-efficacy, efficiency, cost-effectiveness, autonomy, satisfaction with the care provided, and quality of life of partners/informal caregivers. DISCUSSION: The idea behind using MPVC is that MS patients will gain more insight into the individual course of the disease and get a better grip on their symptoms. This knowledge should increase their autonomy, give patients more control of their condition and enable them to better and proactively interact with health care professionals. As the consulting process becomes more efficient with the use of MPVC, MS-related problems could be detected earlier, enabling earlier multidisciplinary care, treatment or modification of the treatment. This could have a positive effect on the quality of life for both the MS patient and his/her partner/informal caregiver, reducing health and social costs.

trial registrationNCT05242731 Clinical Trials.gov. Date of registration: 16 February 2022 retrospectively registered.

Indexed as

Multiple SclerosisSelf-ManagementCaregiversCost-Benefit AnalysisEquivalence Trials as TopicFemaleHumansMaleQuality of LifeRandomized Controlled Trials as TopicSurveys and QuestionnairesMSmonitorMSmonitor-plusMultiple sclerosisQuality of life

Identifiers

PMID36371162
PMCPMC9652934
OpenAlexW4309046080

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.